All In Biotech

Drug Trial Radar · NCT06299826

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

375

Actual

Start

Jun 4, 2024

Primary completion

Feb 10, 2026

Study completion Feb 10, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).

Conditions

  • Chronic Heart Failure

Interventions

  • AZD5462Drug

    Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

  • PlaceboDrug

    Participants will receive matching doses of film-coated tablets of Placebo OD orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A and B: Change from Baseline in Echocardiography ParametersTime frame: From Baseline to Week 25

Locations

57 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Northridge, California

  • Research Site

    Torrance, California

  • Research Site

    Vista, California

  • Research Site

    Miami, Florida

  • Research Site

    Miami Beach, Florida

  • Research Site

    Richmond, Indiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Buffalo, New York

  • Research Site

    Rosedale, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Manassas, Virginia

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Brno, Czechia

  • Research Site

    Jaroměř, Czechia

  • Research Site

    Liberec, Czechia

  • Research Site

    Louny, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Aalborg, Denmark

  • Research Site

    Herning, Denmark

  • Research Site

    Balatonfüred, Hungary

  • Research Site

    Kistarcsa, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Székesfehérvár, Hungary

  • Research Site

    Kochi, India

  • Research Site

    Kolkata, India

  • Research Site

    Surat, India

  • Research Site

    Vadodara, India

  • Research Site

    Fukui-shi, Japan

  • Research Site

    Higashiibaraki-gun, Japan

  • Research Site

    Higashiohmi-shi, Japan

  • Research Site

    Kitakyushu, Japan

  • Research Site

    Kobe, Japan

  • Research Site

    Kumamoto, Japan

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.